These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31017705)

  • 1. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
    Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
    J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men.
    Nobata S; Hishida A; Naito M; Asai Y; Mori A; Kuwabara M; Katase S; Okada R; Morita E; Kawai S; Hamajima N; Wakai K
    Urol Int; 2012; 89(1):39-44. PubMed ID: 22433834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between three genetic variants in kallikrein 3 and prostate cancer risk.
    Ding WH; Ren KW; Yue C; Zou JG; Zuo L; Zhang LF; Bai Y; Okada A; Yasui T; Mi YY
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
    Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
    Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
    Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
    Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.
    Hu J; Qiu Z; Zhang L; Cui F
    Diagn Pathol; 2014 Apr; 9():84. PubMed ID: 24755043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
    Samzadeh M; Hasanzad M; Jamaldini SH; Haghdoost AA; Afshari M; Ziaee SA
    Urol J; 2012; 9(4):691-9. PubMed ID: 23235975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population.
    Dargahi Abbasabad G; Banan Khojasteh SM; Eskandari Naji H; Zamani MR; Hajipour H; Serati-Nouri H
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1717-1720. PubMed ID: 29938471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
    Parikh H; Wang Z; Pettigrew KA; Jia J; Daugherty S; Yeager M; Jacobs KB; Hutchinson A; Burdett L; Cullen M; Qi L; Boland J; Collins I; Albert TJ; Vatten LJ; Hveem K; Njølstad I; Cancel-Tassin G; Cussenot O; Valeri A; Virtamo J; Thun MJ; Feigelson HS; Diver WR; Chatterjee N; Thomas G; Albanes D; Chanock SJ; Hunter DJ; Hoover R; Hayes RB; Berndt SI; Sampson J; Amundadottir L
    Hum Genet; 2011 Jun; 129(6):675-85. PubMed ID: 21318478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
    Binnie MC; Alexander FE; Heald C; Habib FK
    Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
    Li H; Fei X; Shen Y; Wu Z
    Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
    Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
    Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.
    Su XJ; Zeng XT; Fang C; Liu TZ; Wang XH
    Oncotarget; 2017 May; 8(20):33953-33960. PubMed ID: 28430620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
    Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
    Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
    Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
    Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.
    Lin HY; Huang PY; Cheng CH; Tung HY; Fang Z; Berglund AE; Chen A; French-Kwawu J; Harris D; Pow-Sang J; Yamoah K; Cleveland JL; Awasthi S; Rounbehler RJ; Gerke T; Dhillon J; Eeles R; Kote-Jarai Z; Muir K; ; Schleutker J; Pashayan N; ; Neal DE; Nielsen SF; Nordestgaard BG; Gronberg H; Wiklund F; Giles GG; Haiman CA; Travis RC; Stanford JL; Kibel AS; Cybulski C; Khaw KT; Maier C; Thibodeau SN; Teixeira MR; Cannon-Albright L; Brenner H; Kaneva R; Pandha H; ; Srinivasan S; Clements J; Batra J; Park JY
    Sci Rep; 2021 Apr; 11(1):9264. PubMed ID: 33927218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.